Median Technologies (XPAR:ALMDT) Quality Rank

View and export this data going back to 2011. Start your Free Trial

What is Median Technologies Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Median Technologies Quality Rank Related Terms

Thank you for viewing the detailed overview of Median Technologies's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Median Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (XPAR:ALMDT) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

4ZG:Germany

Address

1800 Route Des Cretes, Les Deux Arcs B, Valbonne, FRA, 06560

Website

https://www.mediantechnologies.com

Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services in clinical trials and eyonis for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Geographically, the company generates revenue from EMEA, the USA/Canada, and China.